Xanthines with HM74A receptor activity
The present invention relates to a therapeutically active xanthine derivative compound of formula (I): corresponding pharmaceutical formulations containing, manufacture processes for, methods or uses of such compounds in therapy, in particular for treatment of diseases where under-activation of the HM74A receptor contributes to such diseases or where activation of the HM74A receptor will be beneficial.
1. A compound which is 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione:
a pharmaceutically acceptable salt thereof.
2. A compound which is 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione.
3. A pharmaceutical formulation, which comprises a compound according to claim 1 , and one or more physiologically acceptable diluents, excipients or carriers.
4. A method for treatment of coronary artery disease, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
5. A pharmaceutical formulation, which comprises a compound according to claim 2 , and one or more physiologically acceptable diluents, excipients or carriers.
6. A method for treatment of atherosclerosis, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
7. A method for treatment of mixed dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
8. A method for treatment of diabetic dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
9. A method for treatment of hyperlipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
10. A method for treatment of hyperlipoproteinaemia, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
11. A method for treatment of hypercholesteraemia, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
12. A method for treatment of hypertriglyceridaemia, which comprises administering a therapeutically effective amount of a compound of claim 1 to a human subject in need thereof.
13. A method for treatment of coronary artery disease, which comprises administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.
14. A method for treatment of atherosclerosis, which comprises administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.
15. A method for treatment of mixed dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.
16. A method for treatment of diabetic dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.
17. A method for treatment of hyperlipidaemia, which comprise administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.
18. A method for treatment of hyperlipoproteinaemia, which comprises administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.
19. A method for treatment of hypercholesteraemia, which comprises administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.
20. A method for treatment of hypertriglyceridaemia, which comprises administering a therapeutically effective amount of a compound of claim 2 to a human subject in need thereof.